Travere's chief accounting officer to retire, controller named as successor

Travere Therapeutics disclosed in an 8-K dated July 6, 2026 that Sandra Calvin, chief accounting officer and principal accounting officer of the company, notified Travere of her plan to retire once the company files its Annual Report on Form 10-K, expected in February 2027¹.

The company said it expects John Torell, CFA, CPA, currently Vice President, Controller, to succeed Calvin in the CAO and PAO roles.¹ Travere's board is expected to appoint Torell before Calvin's retirement date to allow for an orderly handover of duties.¹

Torell has been with the company since 2021. In that time he has overseen accounting operations, financial reporting, SEC reporting, technical accounting, and internal controls, and he has held the Vice President, Controller title since 2023.¹

Before joining Travere, Torell spent over two decades in finance roles at Pacific Life Insurance Company. Between 1997 and 2019 he moved up through several posts there, including Vice President Controller, Vice President Assistant Controller, and Vice President of Finance for the Investment Management Division.¹ Earlier in his career, he worked as an Audit Manager at Deloitte.¹ He holds designations as a Chartered Financial Analyst and Certified Public Accountant, and earned a B.A. in Economics-Business from the University of California, Los Angeles.¹

The filing was signed by CEO Eric Dube and dated July 9, 2026.